- Home
- PWR vs ALNY Comparison
PWR vs ALNY Comparison
Compare PWR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWR
- ALNY
- Stock Information
- Founded
- PWR 1997
- ALNY 2002
- Country
- PWR United States
- ALNY United States
- Employees
- PWR N/A
- ALNY N/A
- Industry
- PWR Engineering & Construction
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- PWR Industrials
- ALNY Health Care
- Exchange
- PWR Nasdaq
- ALNY Nasdaq
- Market Cap
- PWR 39.9B
- ALNY 35.0B
- IPO Year
- PWR 1998
- ALNY 2004
- Fundamental
- Price
- PWR $325.88
- ALNY $251.15
- Analyst Decision
- PWR Buy
- ALNY Strong Buy
- Analyst Count
- PWR 22
- ALNY 25
- Target Price
- PWR $334.25
- ALNY $324.54
- AVG Volume (30 Days)
- PWR 1.3M
- ALNY 983.3K
- Earning Date
- PWR 05-01-2025
- ALNY 05-01-2025
- Dividend Yield
- PWR 0.12%
- ALNY N/A
- EPS Growth
- PWR 20.31
- ALNY N/A
- EPS
- PWR 6.19
- ALNY N/A
- Revenue
- PWR $24,874,310,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- PWR $14.67
- ALNY $31.93
- Revenue Next Year
- PWR $9.48
- ALNY $29.20
- P/E Ratio
- PWR $52.62
- ALNY N/A
- Revenue Growth
- PWR 15.77
- ALNY 17.21
- 52 Week Low
- PWR $227.08
- ALNY $144.73
- 52 Week High
- PWR $365.88
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- PWR 71.77
- ALNY 48.55
- Support Level
- PWR $315.45
- ALNY $245.96
- Resistance Level
- PWR $330.75
- ALNY $277.85
- Average True Range (ATR)
- PWR 9.42
- ALNY 10.60
- MACD
- PWR 4.00
- ALNY 1.41
- Stochastic Oscillator
- PWR 93.57
- ALNY 42.07
About PWR Quanta Services Inc.
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric infrastructure and underground utility and infrastructure.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.